Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03483103 · ClinicalTrials.gov registry record · Phase 2
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
A Phase 2 study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT03483103 is a Phase 2 study that has completed, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 74 participants.
The verdict
NCT03483103, a Phase 2 study, has completed, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.
Interventions
- BIOLOGICAL lisocabtagene maraleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03483103
The ClinicalTrials.gov registry entry for NCT03483103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Juno Therapeutics, a Subsidiary of Celgene, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lisocabtagene maraleucel is the first listed.
NCT03483103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03483103 about?
NCT03483103 is a clinical study titled "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)". This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hema...
What is the current status of trial NCT03483103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2018-07-27. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03483103?
The interventions under investigation include: lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03483103?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.